Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
Open Access
Abstract
BACKGROUND: Results from salvage therapy in adult patients with acute lymphocytic leukemia (ALL) are wide‐ranging and depend on several disease and patient characteristics. The objectives of this study were to define the prognosis for adult patients with ALL after first salvage through multivariate analyses of patient and disease characteristics.METHODS: Adults with ALL who had primary resistance to frontline therapy or who had a disease recurrence after a first complete response (CR) duration 55 years, bone marrow blasts ≥20%, and platelet count 55 years, bone marrow blasts ≥20%, platelet count 9/L, albumin level P < .0001; hazard ratio, 0.40; 95% confidence interval, 0.03‐0.72).CONCLUSIONS: The current analyses identified a subset of adults patients ALL in first salvage for whom standard therapies were associated with an extremely poor outcome. The results also confirmed the importance of achieving CR to attain improved survival. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 20 references indexed in Scilit:
- Outcome of adults with acute lymphocytic leukemia after second salvage therapyCancer, 2008
- Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 studyBlood, 2007
- Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trialLeukemia, 2007
- Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801Blood, 2007
- Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 studyBlood, 2006
- Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemiaCancer, 2004
- Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemiaBlood, 2004
- The biology and therapy of adult acute lymphoblastic leukemiaCancer, 2003
- A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasBlood, 2002
- Primary refractory and relapsed adult acute lymphoblastic leukemiaCancer, 1999